Amisulpride

CHEMBL243712 Phase 4 معتمد Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

369.5 g/mol

LogP

1.5

Phase

4

This antipsychotic works by selectively blocking dopamine receptors in the brain to reduce symptoms such as hallucinations and disorganized thinking. It is used in conditions including schizophrenia, and at low doses may help with depressive symptoms associated with bipolar disorder.

الوزن الجزيئي

369,5000 g/mol

LogP

1,50

TPSA

110,00 Å²

قاعدة ليبينسكي للخمسة

ناجح

المجالات العلاجية

Alzheimer's Disease Schizophrenia Bipolar Disorder Generalized Anxiety Disorder Type 2 Diabetes Major Depressive Disorder Chronic Pain

آلية العمل

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

الآلية

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal …

البنية ثنائية الأبعاد

SVG PNG

Cite this structure

Embed this structure

SMILES

CCN1CCCC1CNC(=O)c1cc(S(=O)(=O)CC)c(N)cc1OC

InChI

InChI=1S/C17H27N3O4S/c1-4-20-8-6-7-12(20)11-19-17(21)13-9-16(25(22,23)5-2)14(18)10-15(13)24-3/h9-10,12H,4-8,11,18H2,1-3H3,(H,19,21)

Molecular Formula

C17H27N3O4S

HBD / HBA

2 / 6

الروابط القابلة للدوران

7

الذرات الثقيلة

25

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

الأسئلة الشائعة

This antipsychotic works by selectively blocking dopamine receptors in the brain to reduce symptoms such as hallucinations and disorganized thinking. It is used in conditions including schizophrenia, and at low doses may help with depressive symptoms associated with bipolar disorder.

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.

Yes, Amisulpride is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL243712. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 2159. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

هل تبحث عن معلومات ملائمة للمرضى؟

Amisulpride على PillFYI

البنية

بيانات سريعة

الصيغة الجزيئية: C17H27N3O4S
المرادفات: 1

روابط خارجية

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

إخلاء المسؤولية الطبية

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.